Dr. Adib brings to Triumvira Immunologics over 24 years of medical oncology experience in the biotech and pharmaceutical industries, including 7 successful registrations across various hematologic as well as solid tumor maladies. Most recently, he was the founder of MariCel Clinical Consulting , LLC. Offering strategic services to the biotech industry.
Dr. Adib held multiple seats as a scientific advisory board member at several biotech companies including Imbrium therapeutics a Perdue Pharma subsidiary and a strategic consultant for advanced cell therapy programs through 1st IND at Bellicum pharmaceuticals for the BPX-601: GoCAR-T® currently in Phase I/II clinical trials for solid tumors and at KSQ for eTIL™ autologous cell therapy candidates, KSQ-001.
Past leadership roles include acting Chief Medical Officer at Rain Therapeutics advancing the clinical programs and designing clinical strategy to build the oncology portfolio leading to a successful IPO. In addition, Dr. Adib was Vice president late-stage development at Blueprint Medicines and global therapeutics Head for Solid Tumors at Baxalta, Inc., advancing the development of imalumab in various solid tumors and licensing a nano liposomal irinotecan later approved for pancreatic cancer & leading the clinical evaluation for acquiring Oncaspar from Sigma-Tau Pharmaceuticals (Leadiant Biosciences, Inc.) approved in ALL. He also led the licensing of a CD19 target CAR-T from Precision Biosciences and a PDL1, LAG3, TIM3 check point inhibitor targets from Symphogen a subsidiary of Servier. He was head of hematologic Malignancies at ARIAD leading the global clinical programs for ponatinib in CML later acquired by Takeda.
Dr. Adib has also held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma where he advanced the development of docetaxel in prostate cancer, breast cancer and gastric cancer, enzalutamide in prostate cancer, quizartinib in AML, erlotinib in NSCLC and pancreatic cancer.
Dr. Adib obtained his medical degree from Cairo University School of Medicine, Cairo, Egypt, and completed his postgraduate oncology training at the Anglo-American Hospital Association, Cairo, Egypt and Tufts University School of Medicine– Clinical Pharmacology, Drug Development and Regulation.
Jeffrey Erickson is a life sciences executive with more than 20 years of business development, investor relations, and strategic planning experience leading numerous deals, M&A transactions and R&D collaborations. He joined Triumvira in June 2023 as Vice President of Business Development.
Prior to joining Triumvira, Mr. Erickson was Senior Director of Corporate Development at PhaseBio Pharmaceuticals, where he structured and negotiated terms for licensing and development deals and helped support the company’s commercial planning and financing activities. Before that, Mr. Erickson worked as an analyst at Reneo Capital Management, a healthcare investment fund, and held roles of increasing responsibility at Orexigen Therapeutics, Arena Pharmaceuticals, Amgen, and Amylin Pharmaceuticals. Additionally, Mr. Erickson worked on the sequencing of the human genome at the Whitehead Institute/MIT Center for Genome Research (Broad Institute). Mr. Erickson earned a B.A. in Biochemistry from the University of Pennsylvania.
Ms. Tran joined Triumvira as Senior Vice President, Finance in July 2023 with over 25 years of experience in leading finance teams for private and public biotech companies. Prior to Triumvira, Ms. Tran served as Vice President, Finance for Pardes Biosciences. Prior to Pardes, she was Vice President, Finance at Kura Oncology, Inc. and Senior Director, Finance at Halozyme Therapeutics. Ms. Tran received a B.S. in accounting from the San Diego State University and her Certified Public Accountant designation (inactive) in California.
Dr. Andreas Bader joined Triumvira in 2018. Dr. Bader is a seasoned biotech executive with more than 20 years of experience in oncology drug discovery and development, and business and research strategies. Previously, Dr. Bader acted as Co-Founder and CEO of Orros Biotherapeutics LLC, and as a scientific Co-Founder of Mirna Therapeutics, Inc., where he held multiple leading positions in R&D and led research programs from discovery to the completion of Phase 1 clinical trial. Prior to Mirna, Dr. Bader functioned as the Scientific Lead of the microRNA therapeutics program at Asuragen, Inc. Dr. Bader completed his post-doctoral training at The Scripps Research Institute, La Jolla, California, received his PhD in Biochemistry and his MSc degree in Biology from the University of Innsbruck, Austria.
Ms. Rill joined Triumvira as Chief Technology Officer in June 2018. Prior to Triumvira, Ms. Rill, an accomplished expert in cellular therapy manufacturing, was responsible for the design and qualification of cell & gene therapy laboratories using novel technologies, cGMP vector production facilities, core service laboratories, and translational research laboratories. In addition to her construction, project management and regulatory/QA/QC/(c)GxP knowledge, she brings extensive operational and strategic experience in cell and gene therapy, monoclonal antibody production, and protein production. Ms. Rill will oversee all North American operations for Triumvira.
Ms. Rill’s earlier positions include Vice President of Manufacturing for Cell Medica, Chief Development Officer for Opexa Therapeutics, Laboratory Director of Cell and Gene Therapy at Baylor College of Medicine (Head: Prof. Malcolm Brenner); and Lab Manager of the GMP Cell & Gene Therapy Laboratories at St. Jude Children’s Research Hospital.
Swami Murugappan is an experienced drug development leader serving as the Consulting Chief Medical Officer at Triumvira Immunologics. He is the founder and owner of Trident Bio Consulting Inc., which helps drive strategy and execution for life sciences organizations developing therapeutics for life-threatening illnesses. Previously, he was the Vice President at Nutcracker Therapeutics, a mRNA platform company, where he led non-clinical, clinical, and regulatory functions and was responsible for taking programs from research to IND. Before Nutcracker, Swami was the Executive Director and global product lead for a CD19 CAR-T (Tecartus™) at Kite Pharma, where he led a successful US and EU filing and subsequent FDA approval of Tecartus™ for relapsed and refractory mantle cell lymphoma. Before Kite, Swami worked at Amgen in early and late-phase oncology programs within clinical development and supported global filings and approvals of Vectibix™ and ImLygic™ (first-in-class Oncolytic virus).
Swami is an ABIM board-certified Hematologist and Oncologist. He completed his fellowship training at the University of Washington/Fred Hutchinson Cancer Research Center after his Internal Medicine training at Drexel University. He graduated from Temple University with his Ph.D. in Physiology and received his MD from Chennai Medical College, India.
Robert F. Williamson, III has been active in building biotechnology companies and shareholder value for over two decades. He currently is the President and COO of Triumvira Immunologics. Previously, he was the CBO of OncoMyx, an oncolytic virus company, and CEO of BioTheryX, a protein degradation therapeutics company, raising a $100M crossover round and preparing the company for an IPO. Prior to BioTheryX, Mr. Williamson served as CEO of both PharmAkea and ATXCo, oncology and fibrosis companies financed through a partnership with Celgene, until PharmAkea’s acquisition by Galecto and ATXCo’s acquisition by Blade Therapeutics. Prior, Mr. Williamson was CEO of Arriva Pharmaceuticals, President and COO of Eos Biotechnology, which he sold to Protein Design Labs, and COO of DoubleTwist, Inc. through its acquisition by Merck and Hitachi.
Mr. Williamson also serves as a director and adviser for foundations, private, and public companies. Notably, Mr. Williamson served as an early Director of Pharmasset, Inc., where he helped finance, grow, and advance the company into the public markets and through its acquisition by Gilead in 2011 for $11 billion. Earlier, Mr. Williamson was a partner with The Boston Consulting Group and a research assistant for the Federal Reserve Board. He received a BA in economics from Pomona College and an MBA from Stanford.
